Capstan Therapeutics
Edit

Capstan Therapeutics

https://www.capstantx.com/
Last activity: 01.09.2026
Active - Reference to AbbVie
Categories: BioTechBodyDeliveryDrugEngineeringHealthTechIndustryPlatformTechnologyTools
Capstan Therapeutics is a biotechnology company dedicated to advancing in vivo cell reprogramming. The core platform technology comprises proprietary targeted lipid nanoparticles conjugated with a recombinant protein binder such as monoclonal antibodies (tLNPs) designed to deliver payloads, including mRNA or gene editing tools, that can reprogram specific cell types in vivo. The platform technology has the potential to generate transformative therapies with applications across a broad range of disease areas, including oncology, autoimmune disorders, fibrosis, and monogenic blood disorders. For more information, please visit www.capstantx.com.
Website visits
4.9K /mo.
Mentions
18
Location: United States, California, San Diego
Employees: 51-200
Total raised: $175M
Founded date: 2021

Investors 4

Funding Rounds 1

DateSeriesAmountInvestors
21.03.2024Series B$175MForbion

Mentions in press and media 18

DateTitleDescription
01.09.2026Senticell Raises $7M in Seed FundingSenticell, a Philadelphia, PA-based biotechnology company developing a new class of liquid biopsy built on red blood cell (RBC)-bound nucleic acids, raised $7M in Seed funding. Backers included The Venture City, Capital Factory, Scalpel Ven...
05.03.2026ImmunoScape Signs Clinical Trial MOU With U.S. Cancer Center And Secures Strategic Investment From Leonardo DiCaprioImmunoScape, a Singapore-headquartered biotechnology company developing next-generation T cell receptor (TCR) based cancer immunotherapies, announced that it has signed a memorandum of understanding with a leading National Cancer Institute-...
27.02.2026Gilead Dominates Cell Therapy: $7.8 Billion Arcellx Acquisition Seals FutureGilead Sciences acquired Arcellx for up to $7.8 billion. This landmark acquisition secures full control of anito-cel, a potentially transformative BCMA-directed CAR T-cell therapy for relapsed or refractory multiple myeloma. Anito-cel await...
23.02.2026Фармгигант из США Gilead заплатит до $7,8 млрд за разработчика CAR-T - терапии ArcellxGilead покупает разработчика противораковых препаратов Arcellx за сумму до $7,8 млрд. Gilead согласилась приобрести Arcellx в сделке стоимостью $7,8 млрд, поскольку фармкомпания стремится добавить в свой портфель CAR-T-клеточную терапию про...
10.01.2026UPenn, BioNTech, And Osage University Partners Launch $50 Million Seed Fund To Back Penn Life Science StartupsThe University of Pennsylvania, BioNTech SE, and Osage University Partners (OUP) announced the launch of the $50 million Penn-BioNTech Innovative Therapeutics Seed Fund (PxB Fund), a dedicated venture fund focused on early-stage life scienc...
02.07.2025AbbVie купит Capstan Therapeutics для развития CAR-T терапии-
30.06.2025Forbion Announces Fifth Exit from Forbion Growth Opportunities Fund II with the Sale of Capstan Therapeutics to AbbVie for USD 2.1 Billion• Capstan sale ranks as the largest ever payment for an early-stage private biotech company by upfront consideration value and is Forbion’s seventh consecutive >$1B exit. • Capstan’s in vivo CAR-T platform offers a first-in-class approac...
30.06.2025AbbVie to Acquire Capstan Therapeutics, Further Strengthening Commitment to Transforming Patient Care in Immunology-
11.06.2025Capstan Therapeutics Announces Initiation of Phase 1 Trial of Lead In Vivo CAR-T Therapy, CPTX2309, for Treating Autoimmune Disease- CPTX2309 is a targeted lipid nanoparticle that delivers an anti-CD19 CAR mRNA preferentially to CD8-expressing cytotoxic T cells - mRNA-based approach is designed to achieve rapid, deep, and transient B cell depletion without the need for...
11.06.2025Capstan Therapeutics Announces Initiation of Phase 1 Trial of Lead In Vivo CAR-T Therapy, CPTX2309, for Treating Autoimmune Disease-
Show more

Reviews 0

Sign up to leave a review

Sign up Log In